Article info
PDFClinical and epidemiological research
Extended report
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
- Correspondence to Dr J T Merrill, Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, 825 NE 13th St., Oklahoma City, OK 73104 USA; joan-merrill{at}omrf.org
Citation
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
Publication history
- Received March 25, 2015
- Revised June 18, 2015
- Accepted August 1, 2015
- First published August 20, 2015.
Online issue publication
February 11, 2021
Article Versions
- Previous version (11 February 2021).
- Previous version (11 February 2021).
- Previous version (11 February 2021).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
- Data supplement 1 - Online supplement
Lay summary
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/